First trimester maternal serum MicroRNA expression and pre-eclampsia: a retrospective nested case-control study
- PMID: 41034780
- PMCID: PMC12486713
- DOI: 10.1186/s12884-025-08105-x
First trimester maternal serum MicroRNA expression and pre-eclampsia: a retrospective nested case-control study
Abstract
Background: Numerous circulating microRNAs (miRNAs) have been detected in maternal blood. Initial studies in third trimester demonstrated differential miRNA expression profiles between uncomplicated pregnancies and pregnancies complicated by pre-eclampsia (PE). Recently, studies in first trimester have shown similar differential profiles, however, these studies were often under-powered.
Methods: We conducted a nested case-control study, in which serum samples, taken between 10 and 14 weeks gestation, were obtained from 413 singleton pregnant women, 126 of which later developed PE. Total RNAs were purified and a selection of 46 miRNAs plus two miRNA controls were quantitated by real time quantitative PCR.
Results: Seven of the miRNAs, hsa-miR-181b-5p, -323a-3p, -518b, -363-3p, -20a-5p, -29a-3p, and - 142-3p, could differentiate between uncomplicated pregnancies and pregnancies which develop PE, but only a single miRNA, hsa-miR-363-3p, could differentiate between mild and severe PE. A combination of all seven differentiating miRNAs was the best at discriminating between PE and uncomplicated pregnancies (AUC = 0.879).
Conclusion: First trimester maternal serum miRNA expression profile could differentiate between uncomplicated pregnancies and pregnancies complicated by PE. These circulating miRNA markers have the potential to improve risk assessment of PE in the first trimester, weeks before the onset of symptoms.
Keywords: Circulating MicroRNA; First trimester; Pre-Eclampsia; Quantitative Real-Time PCR.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The Copenhagen First Trimester Screening study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Scientific ethics committee of the cities of Copenhagen and Frederiksberg (No. (KF) 01-288/97) and the Data Protection Agency. Informed consent was obtained from all subjects involved in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Figures
References
-
- Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, McAuliffe F, da Silva Costa F, von Dadelszen P, McIntyre HD, et al. The international federation of gynecology and obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1–33. - PMC - PubMed
-
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy*. Report of the National high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183(1):S1–22. - PubMed
-
- Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1–7. - PubMed
-
- Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-Pathophysiology and clinical presentations: JACC State-of-the-Art review. J Am Coll Cardiol. 2020;76(14):1690–702. - PubMed
-
- Magee LA, Nicolaides KH. Von Dadelszen P: preeclampsia. N Engl J Med. 2022;386(19):1817–32. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
